Oppenheimer Reiterates Outperform on Cellectis, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Hartaj Singh has reiterated an 'Outperform' rating on Cellectis (NASDAQ:CLLS) and maintained a price target of $11.
August 08, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh has reiterated an 'Outperform' rating on Cellectis and maintained a price target of $11.
The reiteration of an 'Outperform' rating by a reputable analyst like Hartaj Singh from Oppenheimer is a positive signal for the stock. The maintained price target of $11 also indicates confidence in the company's performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100